Prescription fills for blockbuster weight loss drugs in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments, according to data released Thursday by drug savings company GoodRx. The figures offer more evidence of the insatiable demand for a buzzy class of medications called GLP-1 and GIP agonists, which mimic gut hormones to suppress appetite and regulate blood sugar. That includes Novo Nordisk's weight loss drug Wegovy and Eli Lilly's obes ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Aubrey Reynolds – Director of Investor Relations Scott Wagner – Interim Chief Executive Officer Karsten Voermann – Chief Financial Officer Conference Call Participants Stephanie Davis – Barclays Charles Rhyee – TD Cowen Lisa Gill – J.P. Morgan Scott Schoenhaus – KeyBanc Stan Berenshteyn – Wells Fargo Securities Sean Dodge – RBC Capital Markets Jailendra Singh – Truist Securities Allen Lutz – ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. | --- | --- | |--------------------------------------- ...

For the quarter ended September 2024, GoodRx Holdings, Inc. (GDRX) reported revenue of $195.25 million, up 8.5% over the same period last year. EPS came in at $0.08, compared to $0.06 in the year-ago quarter.The reported revenue represents a surprise of -0.05% over the Zacks Consensus Estimate of $195.35 million. With the consensus EPS estimate being $0.09, the EPS surprise was -11.11%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%.Over the last four quarters, the ...

Exhibit 99.1 GOODRX REPORTS THIRD QUARTER 2024 RESULTS SANTA MONICA, Calif. -- ( November 7, 2024 ) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights • Revenue1 and Adjusted Revenue1 of $195.3 million • Net income of $4.0 million; Net income margin of 2.0% • Adjusted Net Income1 of $31.9 million; Adjusted Net Income Marg ...

The upcoming report from GoodRx Holdings, Inc. (GDRX) is expected to reveal quarterly earnings of $0.09 per share, indicating an increase of 50% compared to the year-ago period. Analysts forecast revenues of $195.35 million, representing an increase of 8.6% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ear ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, GoodRx insiders caused the company to misrepresent or fail to disclose that (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescr ...

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Try a free 2-week trial today by clicking on our logo below! It has been nearly two years since our initial look at GoodRx Holdings, Inc. (NASDAQ: GDRX ). We concluded that initial article on this 'Busted IPO' by saying the company was going through a lot of changes, the shares were worthy only The Busted IPO Forum is an investing group led by Bret Jensen, Chie ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company. ...